No Data
HC Wainwright & Co. : The Precision BioSciences (DTIL.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $60.00 to $60.00.
HC Wainwright & Co. : The Precision BioSciences (DTIL.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $60.00 to $60.00.
Precision BioSciences to Participate in Upcoming June Investor Conferences
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES
The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22, WU-C
Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene